FATE
What one share of Fate Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of off-the-shelf cellular immunotherapies to patients.
Fate Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.05 |
|---|---|
| Profit | −$1.05 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$0.88 |
| Cash and investments | $0.28 |
| Book value | $1.31 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.14 | −$1.05 | $0.01 | −$0.95 | — | $1.77 |
| 2017 | $0.10 | −$1.02 | $0.04 | −$0.92 | — | $1.47 |
| 2018 | $0.08 | −$1.19 | $0.04 | −$0.73 | — | $2.48 |
| 2019 | $0.16 | −$1.44 | $0.11 | −$1.33 | — | $3.23 |
| 2020 | $0.38 | −$2.10 | $0.06 | −$0.54 | — | $4.38 |
| 2021 | $0.59 | −$2.24 | $0.54 | −$2.25 | — | $7.09 |
| 2022 | $0.99 | −$2.91 | $0.37 | −$2.93 | — | $4.97 |
| 2023 | $0.65 | −$1.64 | $0.06 | −$1.41 | — | $3.74 |
| 2024 | $0.12 | −$1.64 | $0.01 | −$1.09 | — | $2.80 |
| 2025 | $0.06 | −$1.15 | $0.05 | −$0.94 | — | $1.80 |